Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080 · tracked via the Priya Life Science India tracker

Sponsor

Bristol-Myers Squibb

Phase

Phase 2/3

Started

2025-11-05

Last updated

2026-08-25

Condition(s) studied

Non-Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Iza-brenCarboplatinCisplatinPemetrexed

Iza-bren: Specified dose on specified days

Carboplatin: Specified dose on specified days

Cisplatin: Specified dose on specified days

Pemetrexed: Specified dose on specified days

Study summary

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Non-squamous NSCLC, not amenable to treatment in curative intent. * Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation). * Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting. * Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed). Exclusion criteria: * Inadequate organ function and/or bone marrow reserve. * Leptomeningeal metastases or spinal cord compression. * Poorly controlled systemic medical conditions. * Other protocol-defined inclusion/exclusion criteria apply.

Primary outcome measure(s)

Recommended Phase 3 Dose (RP3D) of BMS-986507 — Approximately 3 months after the first dose
Phase 2
Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR) — Up to 3 years
Phase 3

Trial sites (186)

Facility	City	Region	Status
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building	Irvine	California	Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center	Orange	California	Recruiting
Shaw Cancer Center	Edwards	Colorado	Recruiting
Local Institution - 0085	Gainesville	Florida	Withdrawn
Local Institution - 0142	Pembroke Pines	Florida	Not Yet Recruiting
Piedmont Healthcare	Atlanta	Georgia	Recruiting
John B Amos Cancer Center	Columbus	Georgia	Recruiting
Rush University Medical Center	Chicago	Illinois	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	Recruiting
Washington University School of Medicine	St Louis	Missouri	Recruiting
Renown Regional Medical Center	Reno	Nevada	Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island	Mineola	New York	Recruiting
NYU Langone Health	New York	New York	Recruiting
Weill Cornell Medical College	New York	New York	Recruiting
Rochester General Hospital Infectious Disease	Rochester	New York	Recruiting
University Hospitals Cleveland Medical Center	Cleveland	Ohio	Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C	Columbus	Ohio	Recruiting
Providence Cancer Institute Franz Clinic	Portland	Oregon	Recruiting
Providence St. Vincent Medical Center	Portland	Oregon	Recruiting
Oregon Health and Science University	Portland	Oregon	Recruiting
Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	Recruiting
West Penn Allegheny Health	Pittsburgh	Pennsylvania	Recruiting
Local Institution - 0268	Chattanooga	Tennessee	Withdrawn
Tennessee Oncology	Nashville	Tennessee	Recruiting
Local Institution - 0025	Houston	Texas	Not Yet Recruiting
Local Institution - 0173	San Antonio	Texas	Not Yet Recruiting
University of Virginia Health System	Charlottesville	Virginia	Recruiting
Virginia Commonwealth University (Vcu)	Richmond	Virginia	Recruiting
Instituto Alexander Fleming	Ciudad Autónoma de Buenos Aires	Buenos Aires	Recruiting
Local Institution - 0004	ABB	Buenos Aires F.D.	Not Yet Recruiting
Hospital Privado Universitario de Córdoba	Córdoba	Argentina	Recruiting
Local Institution - 0280	Wilrijk	Antwerpen	Not Yet Recruiting
Local Institution - 0161	Auderghem	Bruxelles-Capitale, Région de	Not Yet Recruiting
Local Institution - 0022	Yvoir	Namur	Not Yet Recruiting
Local Institution - 0023	Ghent	Oost-Vlaanderen	Not Yet Recruiting
Local Institution - 0024	Sint-Niklaas	Oost-Vlaanderen	Not Yet Recruiting
Arthur J. E. Child Comprehensive Cancer Centre	Calgary	Alberta	Recruiting
Princess Margaret Cancer Centre	Toronto	Ontario	Recruiting
Local Institution - 0184	Chicoutimi	Quebec	Not Yet Recruiting
Local Institution - 0185	Montreal	Quebec	Not Yet Recruiting

+ 146 more sites — see the full list on the official registry below.

More Bristol-Myers Squibb trials in India

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Active, not recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). Recruiting

Other trials for the same condition

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC Active, not recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer Recruiting

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer Recruiting

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07100080 on ClinicalTrials.gov ↗ ← All trials in India